Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Abbott completes India recall of baby formula products imported from U.S

Published 05/20/2022, 06:53 AM
Updated 05/20/2022, 07:15 AM
© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021.  REUTERS/Brendan McDermid/File Photo

By Leroy Leo

(Reuters) - Abbott Laboratories (NYSE:ABT)' India unit has completed a recall of baby formula products that were manufactured at the company's troubled Michigan facility in the United States, a spokesperson for the company said on Friday.

"The voluntary recall in India impacted Alimentum and EleCare (brands). No other Abbott nutrition products, or Similac products, distributed in India were affected by the recall," the spokesperson told Reuters.

Abbott said earlier this week it had reached an agreement with the U.S. health regulator to resume production at the Michigan plant, which has been shut down over reports of bacterial infections in infants who had consumed products made at the facility.

The company recalled dozens of types of Similac, Alimentum and EleCare powdered formulas in the U.S. and internationally following the infections. Similac supplied in India is produced at Abbott's plant in the country's western state of Gujarat.

The Food Safety and Standards Authority of India has been informed about the recall, according to the spokesperson.

The recall in February by Abbott in the United States created one of the most urgent food shortages in recent history for U.S. families, with other baby formula makers stepping up shipments to the country.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.